Department of Respiratory Medicine, Waikato Hospital, Level 01 Menzies Building, Hamilton 3204, New Zealand.
Thorax. 2011 Sep;66(9):764-8. doi: 10.1136/thx.2010.155333. Epub 2011 Apr 7.
Retrospective studies suggest that plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponin T are often elevated in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) and are associated with increased mortality. These cardiac biomarkers were investigated in an unselected cohort of patients admitted to hospital with exacerbations of COPD.
Consecutive patients with physician-diagnosed COPD exacerbation but without clinical evidence of acute cardiac disease admitted to a public hospital over a 1 year period were studied prospectively. NT-proBNP and troponin T were measured on admission. The primary end point was all-cause mortality at 30 days.
Elevated NT-proBNP (>220 pmol/l) was present in 65/244 patients (27.5%) and significantly predicted 30-day mortality (OR 9.0, 95% CI 3.1 to 26.2, p<0.001). Elevated troponin T (>0.03 μg/l) was found in 40/241 patients (16.6%) and also predicted 30-day mortality (OR 6.3, 95% CI 2.4 to 16.5, p<0.001). These associations persisted after adjusting for other clinical and laboratory predictors of mortality (arterial CO(2) pressure (Paco(2)), body mass index and CURB65 score). NT-proBNP and troponin T levels appeared to have additive associations with mortality: 30-day mortality among patients with abnormalities of both NT-proBNP and troponin T was 15-fold higher than among patients with normal values.
Elevated levels of NT-proBNP and troponin T are strong predictors of early mortality among patients admitted to hospital with acute exacerbations of COPD independently of other known prognostic indicators. The pathophysiological basis for this is unknown, but indicates that cardiac involvement in exacerbations of COPD may be an important determinant of prognosis.
回顾性研究表明,在慢性阻塞性肺疾病(COPD)急性加重的患者中,脑钠肽前体(NT-proBNP)和心肌肌钙蛋白 T 的血浆水平经常升高,并且与死亡率增加相关。这些心脏生物标志物在一组未经选择的因 COPD 加重而住院的患者中进行了研究。
在一年期间,对因 COPD 加重而住院且无急性心脏疾病临床证据的连续患者进行前瞻性研究。入院时测定 NT-proBNP 和肌钙蛋白 T。主要终点是 30 天的全因死亡率。
65/244 例(27.5%)患者存在升高的 NT-proBNP(>220 pmol/l),并显著预测 30 天死亡率(比值比 9.0,95%置信区间 3.1 至 26.2,p<0.001)。40/241 例(16.6%)患者发现升高的肌钙蛋白 T(>0.03 μg/l),并且也预测 30 天死亡率(比值比 6.3,95%置信区间 2.4 至 16.5,p<0.001)。在调整了其他死亡率的临床和实验室预测因素(动脉 CO2 压(Paco2)、体重指数和 CURB65 评分)后,这些关联仍然存在。NT-proBNP 和肌钙蛋白 T 水平似乎与死亡率有相加的关联:NT-proBNP 和肌钙蛋白 T 均异常的患者的 30 天死亡率比正常值患者高 15 倍。
在因 COPD 急性加重而住院的患者中,NT-proBNP 和肌钙蛋白 T 水平升高是早期死亡率的有力预测因素,独立于其他已知的预后指标。其病理生理学基础尚不清楚,但表明 COPD 加重时的心脏受累可能是预后的一个重要决定因素。